Saturday 17 October 2026
Export GRAL’s income statement to Excel — free account
GRAIL, Inc.
GRAL Healthcare Diagnostics & Research
GRAIL, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $147.2 million, up 17.2% from fiscal 2024. In the quarter to June 2026, revenue grew 25.7%, EPS grew 19.5% and free cash flow fell 4.95%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
117.81
17.65
−13.03%
Follow GRAL
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | |
|---|---|---|---|---|
Piotroski F-Score |
6 | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
21.37 | 4.53 | 0.00 | 0.00 |
Altman Z-Score |
0.37 | (5.97) | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(2.86) | (8.53) | 5.21 | — |
P/Operating CF |
(49.32) | (6.09) | (2.05) | (2.05) |
P/B ratio |
1.22 | 0.23 | 0.12 | 0.12 |
Price to Tangible BV |
4.33 | 1.17 | 0.12 | 0.12 |
EV/Sales |
15.23 | (1.54) | 0.00 | 0.00 |
EV/EBITDA |
0.00 | 0.32 | 0.00 | 0.00 |
EV/Operating CF |
(7.50) | 0.34 | (0.41) | (0.41) |
EV/FCF |
(7.47) | 0.33 | (0.40) | (0.40) |
Quick Ratio |
11.58 | 10.19 | 0.70 | — |
Current Ratio |
11.97 | 10.66 | 0.95 | — |
Net Debt/EBITDA |
2.27 | 1.24 | 0.15 | 0.00 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.05 | 0.04 | 0.05 | 0.00 |
Operating CF/Net income |
0.73 | 0.28 | 0.41 | 0.10 |
Capex/Depreciation |
(0.01) | 0.00 | (0.01) | 0.00 |
| (16.07%) | (65.92%) | 0.00% | 0.00% | |
| (13.83%) | (58.78%) | (74.90%) | 0.00% | |
ROIC |
(21.00%) | (78.64%) | (26.69%) | 0.00% |
Return on Tangible Assets |
(44.10%) | (249.63%) | (1,892.43%) | 0.00% |
Average Days of Receivables |
45.37 | 59.03 | 66.42 | 0.00 |
Research and Development Expense of Revenue |
133.04% | 256.68% | 363.83% | 593.30% |
Selling, General and Administrative Expense of Revenue |
187.40% | 292.86% | 389.41% | 533.64% |
Intangible Assets out of Total Assets |
0.63 | 0.68 | 0.91 | 0.00 |
Share Based Compensation of Revenue |
39.60% | 25.70% | 21.83% | 62.50% |
Graham Net Nets |
0.19 | 0.60 | (0.26) | (0.26) |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(13.06%) | (363.81%) | (621.92%) | (621.92%) |
Free Cash Flow Yield |
(9.53%) | (102.27%) | (192.99%) | (192.99%) |
Revenue per Share |
4.00 | 3.94 | 3.00 | 1.79 |
Operating CF per Share |
(8.14) | (18.09) | (19.19) | (18.08) |
Capex per Share |
(0.02) | (0.16) | (0.42) | (0.74) |
Free Cash Flow per Share |
(8.16) | (18.26) | (19.60) | (18.81) |
Cash per Share |
24.61 | 23.93 | 3.13 | 0.00 |
Shareholders Equity per Share |
70.14 | 78.47 | 117.43 | 0.00 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
70.14 | 78.47 | 117.43 | 0.00 |
Free Cash Flow |
(299.92) | (582.36) | (608.69) | (584.17) |
Working Capital |
874.18 | 742.94 | (7.54) | — |
Capital Expenditures |
(0.91) | (5.21) | (12.89) | (22.86) |
Net Current Asset Value |
609.70 | 339.96 | (111.56) | 0.00 |
EV/EBIT |
0.00 | 0.09 | 0.00 | 0.00 |
Capex to Sales |
0.01 | 0.04 | 0.14 | 0.41 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||
Depreciation/Fixed assets |
3.15 | 22.82 | 10.32 | 0.00 |
Cash ROIC |
(8.61%) | (17.83%) | (16.26%) | 0.00% |
Accounts Receivable Turnover |
7.62 | 6.74 | 0.00 | 0.00 |
Accounts Payable Turnover |
60.56 | 16.61 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
3.62 | 8.68 | 38.05 | 0.00 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
19.30 | 18.63 | — | — |
Average Payables |
3.46 | 12.26 | — | — |
Average Assets |
2,952.66 | 3,448.56 | 1,956.91 | — |
Average Common Equity |
2,540.63 | 3,074.80 | — | — |
Columns are period end dates